• 54,029+ CME Conference Registrations Sold
  • 162,088+ Medical Conferences
  • 285 Specialties
  • 11,622 Organizers
  • 158,747 Speakers
  • 159 Countries
  • 4,828 Cities
Duration: CME/CE Points: Author(s):
CME : 0.75

Neurology : Rituximab as treatment Infectious Diseaseor anti-MuSK myasthenia gravis: Multicenter blinded prospective review is organized by American Academy of Neurology (AAN) and will be held during Sep 05, 2017 - Sep 05, 2020. This CME Conference has been approved FOR a maximum of 0.75 AMA PRA Category 1 Credits.

Conference Objectives are :
Upon completion of the article by Hehir et al, the participant should be able to:
• State the most common sex and relative age for patients with anti-MUSK myasthenia gravis in study
• State what percentage of rituximab-treated patients in this study met the primary outcome
• State what secondary outcomes from rituximab treatment were met during this review

Additional details will be posted as soon as they are available.

Intended Audience

Rheumatology, Medicine


Activity Fee : Fee Details will be updated soon


Onsite to Virtual Conference

Market your online event to Million plus Healthcare professionals.